CTIS2023-509220-17-00进行中（未招募）1 期
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors - ART6043C001
Artios Pharma Limited0 个研究点目标入组 120 人开始时间: 2024年4月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have discontinued all previous chemotherapeutic agents, non-hormonal targeted therapy, or investigational drugs for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Endocrine and hormonal therapies for the treatment of cancer must have been discontinued (unless for the treatment of Prostate Cancer) at least 7 days before receiving study medication. Palliative radiotherapy must have completed prior to start of study treatment, Specific to Part A2/A3: Advanced or metastatic cancer with genetic lesions known to cause loss of function of known DDR genes based on available, pre-existing testing, Specific to Part A2/A3: Patients for whom a PARPi is an appropriate treatment option. Patients may have received prior treatment with a PARPi., Specific to Part B: Histologically or cytologically confirmed HER2-ve locally advanced or metastatic carcinoma of the breast., Specific to Part B: Documentation of a deleterious or suspected deleterious g/sBRCA mutation and/or PALB2 mutation., Specific to Part B: Patients must have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy., Specific to Part B: Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated., Specific to Part B: Patients must have received no or =1 month of prior treatment with a PARPi., Resolution of all toxicities of prior therapy or surgical procedures., Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale, Have adequate organ function, Patients of childbearing potential and patients with partners of childbearing potential must be willing to follow contraceptive requirements during their participation in the study and for the appropriate period after the last dose of study drug, Have an estimated life expectancy of =12 weeks, in the judgment of the investigator., Specific to Part A1: Advanced or metastatic cancer with genetic lesions known to cause loss of function of known DDR genes, Specific to Part A1 for Spain only: Patient that is not eligible for curative treatment, for whom standard of care therapies have failed., Specific to Part A1/A2/A3: At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation (prostate cancer patients only).
排除标准
- •Patients who are pregnant (lack of pregnancy confirmed by a urine or serum pregnancy test within 5 days prior to receiving first dose of study treatment in patients of childbearing potential) or breast feeding., Known hypersensitivity/history of allergy to any of the components of ART6043, olaparib or niraparib (as applicable)., Specific to Part B: First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy., Specific to Part B: Inflammatory breast cancer., Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to the protocol., Patients with Myelodysplastic syndrome (MDS)/Acute myeloid leukemia (AML) or with features suggestive of MDS/AML., Have ongoing interstitial lung disease or pneumonitis., Have any major gastrointestinal issues that could impact absorption of ART6043, Niraparib or Olaparib., Patients with brain metastases (patients with treated brain metastases could be eligible if follow-up brain imaging after central nervous system-directed therapy shows no evidence of progression)., Have received a live vaccine within 30 days before the first dose of study treatment., Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access), or minor surgery within 1 week of entry into the study., Have a significant bleeding disorder or vasculitis or had a Grade =3 bleeding episode within 12 weeks prior to enrollment.
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II Open-label, Multi-center Study of the Safety and Effectiveness of Increasing Doses of IMCgp100 in Patients with Advanced Uveal MelanomaAdvanced Uveal MelanomaMedDRA version: 20.0Level: PTClassification code 10061252Term: Intraocular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004222-34-ESImmunocore Limited146
进行中（未招募）
1 期
Open-label, Multi-center Study to Assess the Safety and Preliminary Efficacy of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)Relapsed/Refractory Classical Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2021-003569-36-DKAstraZeneca AB,180
进行中（未招募）
1 期
Open-label, Multi-center Study to Assess the Safety and Preliminary Efficacy of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)Relapse/Refractory Classical Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2021-003569-36-ESAstraZeneca AB,180
进行中（未招募）
1 期
Safety and Preliminary Efficacy Assessment of AZD7789 inPatients With Relapsed or Refractory Classical HodgkinLymphomaRelapsed/Refractory Classical Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code: 10080208Term: Classical Hodgkin lymphoma Class: 10029104CTIS2022-502773-41-00AstraZeneca AB190
进行中（未招募）
不适用
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid TumoursEUCTR2008-002606-18-GBAstrazeneca AB100